Licensing status

Publication and contact information

Hepatic disease

Liver fibrosis

CXC chemokine receptor 4 (CXCR4; NPY3R); CXCR7

Mouse studies suggest agonizing CXCR7 or inhibiting CXCR4 could help prevent or treat liver fibrosis. In mouse models of chronic liver injury, Cxcr7 deficiency in liver endothelial cells increased hepatic levels of collagen and other profibrotic factors compared with wild-type Cxcr7 expression. In the models, Cxcr4 deficiency or a Cxcr7 agonist decreased hepatic levels of profibrotic factors compared with wild-type Cxcr4 expression or vehicle. Planned work includes further testing of CXCR7 agonists in mouse models of liver injury.
Sanofi markets Mozobil plerixafor (AMD3100), a synthetic CXCR4 antagonist, to treat multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) and has the compound in Phase I testing to treat acute myelogenous leukemia (AML).
TaiGen Biotechnology Co. Ltd. has the CXCR4 inhibitor burixafor (TG-0054) in Phase II testing for stem cell transplant in patients with cancer.
Biokine Therapeutics Ltd. and BioLineRx Ltd. have the CXCR4 antagonist BL-8040 in Phase II testing to treat AML and Phase I/II trials to treat cancer (see Balancing act in liver fibrosis, page 9).

SciBX 6(48); doi:10.1038/scibx.2013.1391
Published online Dec. 19, 2013

Patented by Weill Cornell Medical College; unlicensed

Ding, B.-S. et al. Nature;
published online Nov. 20, 2013;
Contact: Shahin Rafii, Weill Cornell Medical College, New York, N.Y.